Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 20, 2023

Long-Term Activity of Vemurafenib in Patients With BRAF-Mutated Advanced Cancers Other Than BRAFV600-Mutated Melanoma and NSCLC



Additional Info

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma
ESMO Open 2023 Nov 01;8(6)102038, JY Blay, C Cropet, S Mansard, Y Loriot, C De La Fouchardière, J Haroche, D Topart, D Tougeron, B You, A Italiano, V Le Brun-Ly, JM Ferrero, N Penel, M Fabbro, X Troussard, D Malka, I Ray-Coquard, S Leboulleux, A Fléchon, E Maubec, J Charles, S Dalle, S Taieb, GCTE Garcia, AM Mandache, N Colignon, M Gavrel, F Nowak, N Hoog Labouret, C Mahier Aït Oukhatar, C Gomez-Roca

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading